Navigation Links
Einstein-Montefiore Center for AIDS Research receives $8.5M award from NIH
Date:5/27/2008

May 27, 2008 (BRONX, NY) The Albert Einstein College of Medicine of Yeshiva University has been awarded a five-year grant of more than $8.5 million from the National Institutes of Health (NIH). The renewal grant will fund the Einstein-Montefiore Center for AIDS Research (CFAR) at Einstein and Montefiore Medical Center, the University Hospital for the College, that together conduct some of the most important, fundamental research contributing to our understanding of how HIV infection causes AIDS, as well as develop and provide innovative treatment and support programs for patients. The increased funding received by the CFAR also renews its designation as an NIH CFAR site.

The award of this grant and the Centers designation as an NIH CFAR after a highly competitive review and selection process is a tribute to our position as one of the leading AIDS research programs in the country, says Dr. Harris Goldstein, director of the CFAR and professor of pediatrics and of microbiology & immunology, as well as Assistant Dean for Scientific Resources at Einstein and an attending physician in the Division of Allergy and Immunology at Montefiore. Our commitment to, and preeminent involvement in, AIDS research goes back more than 25 years, with Einstein and Montefiore investigators at the forefront of AIDS research and patient care since the emergence of the AIDS epidemic.

The CFAR coordinates the diverse research activities of hundreds of investigators at Einstein and Montefiore, who are working with over 70 NIH-funded faculty members representing more than 15 basic and clinical departments. The new grant will support the continued growth of AIDS research at both of the Centers research sites, in particular research programs involved in investigating three Core areas: HIV biology and therapeutics; HIV-associated pathogens and HIV-related epidemiology; and behavior and substance abuse. In addition, the grant will fund further expansion of Einstein and Montefiore International AIDS-related research and treatment programs that have been established in Rwanda, Ethiopia, South Africa, India and Guatemala.

The many contributions that Einstein and Montefiore researchers and clinicians have made to date include:

  • being among the first to describe AIDS in injection drug users and to demonstrate transmission by needle sharing and heterosexual intercourse;

  • being the first in the world to identify pediatric AIDS as a distinct disease and to establish a day-care center for children with AIDS;

  • identifying radioimmunotherapy (RIT) as a possible therapy for preventing or treating HIV infection;

  • developing a vaccine to combat extremely drug resistant tuberculosis (XDR-TB), which affects many AIDS patients in developing nations because of their impaired immune systems;

  • establishing clinics and research programs in developing nations, such as Rwanda, Ethiopia, South Africa, India and Guatemala, to provide much-needed treatment, as well as education about prevention; and

  • genetically engineering immune cells to redirect their infection-fighting ability toward killing HIV-infected cells, a strategy which could ultimately lead to an entirely new approach for combating AIDS and other viral diseases.

By its design, the CFAR is set up to facilitate interactions between, and collaborations among, Einstein and Montefiore basic and clinical investigators, said Dr. Allen M. Spiegel, The Marilyn and Stanley M. Katz Dean at Einstein. This is particularly helpful in accelerating the translation of research about how HIV causes AIDS into therapies that treat and prevent HIV infection.

From the earliest days of the AIDS epidemic, Montefiore clinicians and researchers at Einstein recognized the coming medical crisis, said Steven M. Safyer, MD, president and CEO of Montefiore. By combining our respective clinical and research expertise, we created what still stands as one of the most prestigious multi-disciplinary programs in the nation. The prestige and recognition that come with this NIH grant will enable both institutions to continue to find new ways to treat and care for patients in our community and beyond, and to share valuable knowledge with scientists and clinicians around the world, said Dr. Safyer.

The CFAR was first designated as an NIH CFAR site in 2003 and is currently one of just 20 such sites in the nation.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Verity Radiation Therapy Becomes Second U.S. Medical Center to Treat Cancer Patients Using RapidArc(TM) Radiotherapy Technology
2. Harvard Pilgrim Health Care and Perot Systems Named as Best Partnership by Outsourcing Center
3. The Chopra Center Co-founders Bring Mind-Body Healing to New York City
4. Fat Spaniel String Monitoring Service Keeps Close Watch on Boulder Cancer Center Solar Array
5. Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP
6. Ohio State University Medical Center to Test Efficacy of Hyperbaric Oxygen Medicine on Stroke Victims
7. eHealth Initiative and the Center for Improving Medication Management to Present Report Detailing Both Impact of E-Prescriptions on U.S. Health Care System and Guidelines for Achieving Optimal Results
8. Rep. Boozman, AOA Officials Tour Military Eye Care Facilities at Walter Reed Army Medical Center
9. Reproductive Science Center and Lowell General Hospital Announce Partnership in Infertility Treatment
10. Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM)
11. With age comes a sense of peace and calm, population research center study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... , June 23, 2016 The ... it continues to present great opportunities to investors. Stock-Callers.com ... today: Intrexon Corp. (NYSE: XON ), Vertex ... Inc. (NASDAQ: ARNA ), and Regeneron Pharmaceuticals ... these stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: